- Home
- MCRB vs SRFM Comparison
MCRB vs SRFM Comparison
Compare MCRB & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | SRFM |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 123.3M |
| IPO Year | 2015 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MCRB | SRFM |
|---|---|---|
| Price | $8.84 | $1.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $14.00 | $3.25 |
| AVG Volume (30 Days) | 39.3K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.69 |
| EPS | ★ 0.64 | N/A |
| Revenue | $789,000.00 | ★ $106,557,000.00 |
| Revenue This Year | N/A | $25.90 |
| Revenue Next Year | N/A | $20.72 |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $1.04 |
| 52 Week High | $29.98 | $9.35 |
Technical Indicators
Market Signals| Indicator | MCRB | SRFM |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 50.31 |
| Support Level | $7.98 | $1.04 |
| Resistance Level | $9.53 | $2.16 |
| Average True Range (ATR) | 0.59 | 0.10 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 40.59 | 93.06 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.